Readmission rates and outcomes in adults with and without COVID-19 following inpatient chemotherapy admission: A nationwide analysis.
Cancer
Chemotherapy
Coronavirus disease 2019 pandemic
Healthcare cost
Nationwide readmission database
Readmission rates
Journal
World journal of clinical oncology
ISSN: 2218-4333
Titre abrégé: World J Clin Oncol
Pays: United States
ID NLM: 101549149
Informations de publication
Date de publication:
24 Aug 2023
24 Aug 2023
Historique:
received:
07
05
2023
revised:
12
07
2023
accepted:
08
08
2023
medline:
13
9
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic has received considerable attention in the scientific community due to its impact on healthcare systems and various diseases. However, little focus has been given to its effect on cancer treatment. To determine the effect of COVID-19 pandemic on cancer patients' care. A retrospective review of a Nationwide Readmission Database (NRD) was conducted to analyze hospitalization patterns of patients receiving inpatient chemotherapy (IPCT) during the COVID-19 pandemic in 2020. Two cohorts were defined based on readmission within 30 d and 90 d. Demographic information, readmission rates, hospital-specific variables, length of hospital stay (LOS), and treatment costs were analyzed. Comorbidities were assessed using the Elixhauser comorbidity index. Multivariate Cox regression analysis was performed to identify independent predictors of readmission. Statistical analysis was conducted using Stata A total of 87755 hospitalizations for IPCT were identified during the pandemic. Among the 30-day index admission cohort, 55005 patients were included, with 32903 readmissions observed, resulting in a readmission rate of 59.8%. For the 90-day index admission cohort, 33142 patients were included, with 24503 readmissions observed, leading to a readmission rate of 73.93%. The most common causes of readmission included encounters with chemotherapy (66.7%), neutropenia (4.36%), and sepsis (3.3%). Comorbidities were significantly higher among readmitted hospitalizations compared to index hospitalizations in both readmission cohorts. The total cost of readmission for both cohorts amounted to 1193000000.00 dollars. Major predictors of 30-day readmission included peripheral vascular disorders [Hazard ratio (HR) = 1.09, The COVID-19 pandemic has significantly impacted the management of patients undergoing IPCT. These findings highlight the urgent need for a more strategic approach to the care of patients receiving IPCT during pandemics.
Sections du résumé
BACKGROUND
BACKGROUND
The coronavirus disease 2019 (COVID-19) pandemic has received considerable attention in the scientific community due to its impact on healthcare systems and various diseases. However, little focus has been given to its effect on cancer treatment.
AIM
OBJECTIVE
To determine the effect of COVID-19 pandemic on cancer patients' care.
METHODS
METHODS
A retrospective review of a Nationwide Readmission Database (NRD) was conducted to analyze hospitalization patterns of patients receiving inpatient chemotherapy (IPCT) during the COVID-19 pandemic in 2020. Two cohorts were defined based on readmission within 30 d and 90 d. Demographic information, readmission rates, hospital-specific variables, length of hospital stay (LOS), and treatment costs were analyzed. Comorbidities were assessed using the Elixhauser comorbidity index. Multivariate Cox regression analysis was performed to identify independent predictors of readmission. Statistical analysis was conducted using Stata
RESULTS
RESULTS
A total of 87755 hospitalizations for IPCT were identified during the pandemic. Among the 30-day index admission cohort, 55005 patients were included, with 32903 readmissions observed, resulting in a readmission rate of 59.8%. For the 90-day index admission cohort, 33142 patients were included, with 24503 readmissions observed, leading to a readmission rate of 73.93%. The most common causes of readmission included encounters with chemotherapy (66.7%), neutropenia (4.36%), and sepsis (3.3%). Comorbidities were significantly higher among readmitted hospitalizations compared to index hospitalizations in both readmission cohorts. The total cost of readmission for both cohorts amounted to 1193000000.00 dollars. Major predictors of 30-day readmission included peripheral vascular disorders [Hazard ratio (HR) = 1.09,
CONCLUSION
CONCLUSIONS
The COVID-19 pandemic has significantly impacted the management of patients undergoing IPCT. These findings highlight the urgent need for a more strategic approach to the care of patients receiving IPCT during pandemics.
Identifiants
pubmed: 37700808
doi: 10.5306/wjco.v14.i8.311
pmc: PMC10494557
doi:
Types de publication
Journal Article
Langues
eng
Pagination
311-323Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors hereby declare no conflict of interest.
Références
BMJ Glob Health. 2021 Dec;6(12):
pubmed: 34853031
Eat Behav. 2021 Dec;43:101573
pubmed: 34619464
Arthritis Care Res (Hoboken). 2017 Nov;69(11):1668-1675
pubmed: 28118530
JAMA. 2013 Feb 13;309(6):587-93
pubmed: 23403683
Circ Heart Fail. 2021 Apr;14(4):e008335
pubmed: 33866827
J Hosp Med. 2021 Aug 18;:
pubmed: 34424190
Cancer Med. 2021 Sep;10(18):6199-6206
pubmed: 34313031
J Natl Cancer Inst. 2013 May 1;105(9):634-42
pubmed: 23482657
Clin Orthop Relat Res. 2014 Sep;472(9):2878-86
pubmed: 24867450
BMJ Open. 2021 Mar 16;11(3):e045343
pubmed: 33727273
Front Public Health. 2022 May 23;10:898254
pubmed: 35677770
JAMA Oncol. 2019 Jul 01;5(7):1028-1035
pubmed: 30946433
Intern Med J. 2013 Jul;43(7):798-802
pubmed: 23461391
JAMA. 2011 Oct 26;306(16):1794-5
pubmed: 22028355
Curr Med Res Pract. 2020 Mar-Apr;10(2):78-79
pubmed: 32292804
JAMA. 2021 Nov 16;326(19):1909-1910
pubmed: 34714325
Front Med (Lausanne). 2022 Mar 17;9:846352
pubmed: 35372416
Ann Surg Oncol. 2016 Jun;23(6):1941-7
pubmed: 26842489
Viruses. 2021 Jan 29;13(2):
pubmed: 33572857
BMJ Open. 2022 Apr 11;12(4):e054690
pubmed: 35410925
Gastroenterology Res. 2022 Oct;15(5):253-262
pubmed: 36407807
ACS Infect Dis. 2022 Sep 9;8(9):1758-1814
pubmed: 35940589
J Surg Res. 2022 Sep;277:365-371
pubmed: 35569214
Oncol Nurs Forum. 2017 Mar 1;44(2):176-191
pubmed: 28222076
Health Inf Sci Syst. 2022 Sep 2;10(1):25
pubmed: 36065327
BMJ Open Respir Res. 2021 Mar;8(1):
pubmed: 33771814
Postgrad Med J. 2020 Dec;96(1142):753-758
pubmed: 32563999
Cureus. 2020 Jul 21;12(7):e9308
pubmed: 32839677